Medicilon assisted PA1010 tablets with implied permission for clinical trials

저자：medicilon   업로드：2020-03-15  조회수：

On March 10, 2020, PA1010 tablets, which are independently developed by Zhejiang Bolaatu Medical Technology Co., Ltd, obtained the implied license for NMPA clinical trials. This is the first new drug declared by Bolaatu. PA1010 is a new class I drug for chronic hepatitis B (CHB).

Zhejiang Bolaatu is a new drug research and development company under the Zhejiang Kangde Pharmaceutical Co., Ltd. Bolaatu is mainly focusing on hepatitis B and their major business is the development of antiviral drugs and asthma drugs.

Medicilon collaborated with Bolaatu in the research and development of PA1010 tablets and completed the related work of API development and quality research to accelerate the development of new drugs for PA1010 tablets.

Medicilon has established a platform for research and development of cGMP APIs and developed the GMP APIs for clinical trials for innovative drug companies. Medicilon vigorously develops new technologies and establishes a safety assessment laboratory in the process of drug substance synthesis, which meets the requirements of regulations and ICH guidelines.

이전：Nation Mourned Covid19 Victims in China at April 4th

다음에：Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08